Lachat, Mario |
NCT02365454: NEXUS™ Aortic Arch Stent Graft System First In Man Study |
|
|
| Completed | N/A | 18 | Europe, RoW | Stent Graft Placement (Nexus) | Endospan Ltd. | Thoracic Aortic Arch Disease, Thoracic Aortic Aneurysm | 11/18 | 06/23 | | |
ARCUS, NCT05636527: Further Evaluation of Safety and Performance of the NEXUS Aortic Arch Stent Graft System and the Custom-Made NEXUS DUO™ Aortic Arch Stent Graft System |
|
|
| Recruiting | N/A | 60 | Europe | | Endospan Ltd. | AAT9 | 07/25 | 07/30 | | |
Iglesias, Juan F |
NCT06409117: 3rd Generation Resorbable Magnesium Scaffolds vs Biodegradable Polymer Stents in NSTE/ACS |
|
|
| Not yet recruiting | 4 | 220 | Europe | Percutaneous coronary intervention | Konstantinos Toutouzas, Centre Hospitalier Universitaire Saint Pierre, Université Catholique de Louvain, University Hospital of Leuven Leuven, University of Patras, Ippokrateio General Hospital of Thessaloniki | Acute Coronary Syndrome, Coronary Artery Disease | 12/27 | 12/27 | | |
| Terminated | 2 | 29 | Europe | conestat alfa or placebo, Ruconest | Pharming Technologies B.V. | Non-ST Elevation Myocardial Infarction (NSTEMI) | 04/23 | 04/23 | | |
| Recruiting | N/A | 70 | Europe | CorFlow Controlled Flow Infusion System - CoFI™ | CorFlow Therapeutics AG | STEMI - ST Elevation Myocardial Infarction, Microvascular Obstruction | 12/23 | 06/24 | | |
| Completed | N/A | 1300 | Europe | | University Hospital, Geneva, Insel Gruppe AG, University Hospital Bern | Coronary Artery Disease, Acute Coronary Syndrome | 04/23 | 10/23 | | |
NCT02710435: REDUCER-I: An Observational Study of the Neovasc Reducer™ System |
|
|
| Active, not recruiting | N/A | 400 | Europe | Reducer System, Reducer | Neovasc Inc., Shockwave Medical, Inc. | Angina Pectoris, Angina Pectoris, Stable, Chronic Stable Angina | 11/23 | 12/28 | | |
SALINE, NCT04284345: Saline-induced Distal to Aortic Coronary Pressure Ratio vs. Resting and Hyperemic Indices of Coronary Artery Stenosis Severity |
|
|
| Completed | N/A | 90 | Europe | Saline Pd/Pa | University Hospital, Geneva | Coronary Stenosis | 01/24 | 01/24 | | |
STARS DAPT, NCT05785897: STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT |
|
|
| Not yet recruiting | N/A | 350 | Europe | Successful primary PCI, defined as primary PCI of the culprit lesion with ≥1 Abluminus NP polymer-free sirolimus-based nanocarrier eluting stent (Concept Medical Inc., India) implantation, 'All-comer' subjects with acute STEMI undergoing primary PCI according to current ESC guidelines will be eligible., Pre-treatment with DAPT consisting of aspirin and a potent P2Y12 receptor inhibitor, either Ticagrelor or Prasugrel at the time of STEMI diagnosis, or at the very latest at the time of primary PCI | IGLESIAS Juan Fernando, Clinical Trials Unit University of Bern | ST Elevation Myocardial Infarction | 03/26 | 03/27 | | |
| Active, not recruiting | N/A | 3326 | Europe, RoW | SELUTION SLR, DES | M.A. Med Alliance S.A. | Coronary Artery Disease | 08/25 | 07/30 | | |
BIOHYBRID, NCT06710210: Hybrid Percutaneous Coronary Intervention Combining a Bioresorbable Scaffold With Drug-coated Balloons Versus a Conventional Drug-eluting Stent-based Strategy in Patients With Long and Diffuse Coronary Artery Disease |
|
|
| Not yet recruiting | N/A | 150 | Europe | PCI with a bioresorbable scaffold and drug-coated balloon(s), PCI with drug-eluting stent(s) | University Hospital, Geneva, Clinical Trials Unit Bern (CTU) | Coronary Artery Disease, Diffuse Coronary Artery Disease, Percutaneous Coronary Intervention (PCI) | 12/26 | 12/27 | | |
| Recruiting | N/A | 708 | Europe | Complex PCI with Ultimaster family drug-eluting stent (Terumo Corp., Japan) | IGLESIAS Juan Fernando, University of Bern | Vascular Access Site Occlusion | 05/25 | 05/26 | | |
ULTRA-LM, NCT05650411: P2Y12 Inhibitor-based Single Antiplatelet Therapy After a Short DAPT vs. Conventional DAPT Following PCI With a Polymer-free Drug-coated Stent for Unprotected Left Main Coronary Artery Disease |
|
|
| Not yet recruiting | N/A | 766 | Europe | LMCA PCI with Biofreedom Ultra drug-coated stent (Biosensors International, Switzerland), P2Y12 inhibitor-based SAPT after short DAPT, Conventional DAPT | IGLESIAS Juan Fernando, University of Bern | Left Main Coronary Artery Stenosis | 03/27 | 03/30 | | |
| Recruiting | N/A | 3000 | Europe, RoW | The Paradise Ultrasound Renal Denervation System | ReCor Medical, Inc. | Hypertension | 12/30 | 12/31 | | |
Maggiorini, Marco |
NCT03643367: Sevoflurane Sedation in Patients With Septic Shock |
|
|
| Not yet recruiting | 2 | 153 | Europe | Sevoflurane, Control Group, Propofol | University of Zurich, Kantonsspital Münsterlingen, Triemli Hospital, Waid City Hospital, Zurich | Shock, Septic | 02/25 | 11/25 | | |
Kesterke, Rahel |
ULTRA-LM, NCT05650411: P2Y12 Inhibitor-based Single Antiplatelet Therapy After a Short DAPT vs. Conventional DAPT Following PCI With a Polymer-free Drug-coated Stent for Unprotected Left Main Coronary Artery Disease |
|
|
| Not yet recruiting | N/A | 766 | Europe | LMCA PCI with Biofreedom Ultra drug-coated stent (Biosensors International, Switzerland), P2Y12 inhibitor-based SAPT after short DAPT, Conventional DAPT | IGLESIAS Juan Fernando, University of Bern | Left Main Coronary Artery Stenosis | 03/27 | 03/30 | | |